Histone Deacetylase Inhibitor Mpt0b291 Suppresses Glioma Growth In Vitro And In Vivo Partially Through Acetylation Of P53

Background: Histone deacetylase (HDAC) inhibitors have emerged as a new class of anti-tumor agents for various types of tumors, including glioblastoma.Methods and results: We found that a novel HDAC inhibitor, MPT0B291, significantly reduced the cell viability and increased cell death of human and rat glioma cell lines, but not in normal astrocytes. We also demonstrated that MPT0B291 suppressed proliferation by inducing G1 phase cell cycle arrest and increased apoptosis in human and rat glioma cell lines by flow cytometry and immunocytochemistry. We further investigated the anti-tumor effects of MPT0B291 in xenograft (mouse) and allograft (rat) models. The IVIS200 images and histological analysis indicated MPT0B291 (25 mg/kg, p. o.) reduced tumor volume. Mechanistically, MPT0B291 increased phosphorylation and acetylation/activation of p53 and increased mRNA levels of the apoptosis related genes PUMA, Bax, and Apafl as well as increased protein level of PUMA, Apafl in C6 cell line. The expression of cell cycle related gene p21 was also increased and Cd1<2, Cd1<4 were decreased by MPT0B291.Conclusion: Our study highlights the anti-tumor efficacy of a novel compound MPT0B291 on glioma growth.